Screener
Xenon Pharmaceuticals XENE PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 945,868 | 560,649 |
| Marketable securities, long-term (note 5) | 314,411 | 37,152 |
| Operating lease right-of-use asset, net (note 6) | 5,385 | 6,626 |
| Property, plant and equipment, net | 7,774 | 8,721 |
| Deferred tax assets | 14,361 | 12,864 |
| Prepaid expenses, long-term | 7,973 | 7,151 |
| Total assets | $1,295,772 | $633,163 |
| Liabilities and shareholders’ equity |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's PP&E (net)?
- Xenon Pharmaceuticals (XENE) reported PP&E (net) of $7.77M in Q2 2026.
- How has Xenon Pharmaceuticals's PP&E (net) changed year-over-year?
- Xenon Pharmaceuticals's PP&E (net) decreased by 15.5% year-over-year, from $9.21M to $7.77M.
- What is the long-term trend for Xenon Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's PP&E (net) has grown at a 19.7% compound annual growth rate (CAGR), from $3.55M to $8.72M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Xenon Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude